Artera was founded in 2021 by Andre Esteva. The company has not publicly endorsed plans to participate in an IPO.
Artera is the developer of AI-powered predictive and prognostic cancer tests. The company's flagship product, the ArteraAI Prostate test, aims to predict the benefits of therapy for patients with localized prostate cancer. As of the public launch in March 2023, Artera had raised $90 million in venture capital funding from investors including Coatue, Johnson & Johnson Innovation, Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital, and Marc Benioff. Artera did not disclose valuation figures at the time of launch.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/25/2022 | Series Seed-3 | $75MM | $xx.xx | $396.01MM | Walden Catalyst | |
Price per Share
$xx.xx
Shares Outstanding
9,431,850
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Walden Catalyst
|
||||||
04/25/2022 | Series Seed-2 | $14.3MM | $xx.xx | $396.01MM | Walden Catalyst | |
Price per Share
$xx.xx
Shares Outstanding
6,030,037
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Walden Catalyst
|
||||||
04/25/2022 | Series Seed-1 | $199,999 | $xx.xx | $396.01MM | Walden Catalyst | |
Price per Share
$xx.xx
Shares Outstanding
7,168,458
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Walden Catalyst
|